Navigation Links
Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
Date:5/17/2010

WELLESLEY HILLS, Mass., May 17 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the MRI imaging intellectual properties of the EP-3600 MRI imaging agent, which will be auctioned on May 28, 2010, include potential royalties of 2% each from the development and commercialization of three additional programs related to MRI imaging agents and/or technologies.  There is also a fourth program related to one MRI imaging agent with a potential royalty of 4-6% from the development and commercialization with a buy-up option to increase royalties up to 15-17%.  Furthermore, the purchase of EP-3600 also includes the rights to develop and commercialize collagen binding therapeutics using the same proprietary technology that resulted in the discovery of EP-3600.  Collagen binding therapeutics could be targeted toward the treatment of debilitating diseases such as scleroderma.  

The assets of Epix were transferred to him on July 20, 2009 and he is liquidating them for the benefit of Epix creditors.  He recently reached an agreement with Bayer Schering Pharma that permits the sale of the MRI imaging programs.  

EP-3600 and related analogs are gadolinium-based MRI imaging agents with a potential indication for myocardial perfusion imaging.  These lead compounds represent first-in-class collagen binding agents that are currently in preclinical development.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office -

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... CHICAGO, Ill. , July 23, 2014 ... OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ... OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. ... second-quarter 2014 financial results on Friday, July 25, 2014, before ... webcast of the earnings conference call at 8 a.m. Central ...
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid ... Network-Quality Improvement Organization (QIN-QIO) contract to a partnership led ... Effective August 1, WVMI will launch Quality Insights Quality ... Pennsylvania , Delaware ... The Network will engage providers and the community in ...
(Date:7/23/2014)... 2014 Research and Markets   ... Electrophysiology Ablation Catheters Market 2014-2018" report to ... Catheter ablation is a minimally ... electrical pathways from sections of the heart that ... arrhythmias). Cardiac arrhythmias can be of several types, ...
Breaking Medicine Technology:AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3
... Truphatek has successfully enticed one of the best known professionals in ... , Dan White , formerly of ... a new US subsidiary of Truphatek http://www.truphatek.com/ ... I may be reached after this week at 573-240-0002 or by e-mail ...
... , NEWARK, Calif., Oct. 6 Extending its reach ... North America, Inc. has signed ... distribute its perfluoroelastomer sealing components and provide local applications ... are integral in the ultraclean manufacturing of semiconductors, solar ...
Cached Medicine Technology:New Places and People - Truphatek opens USA subsidiary 2New Places and People - Truphatek opens USA subsidiary 3Applied Seals North America Extends Global Network With Addition of Distributor in Europe 2
(Date:7/23/2014)... Dallas, TX (PRWEB) July 23, 2014 ... could be diminished using non-surgical techniques, according to a ... of puffy eyes serum sold in the U.S. is ... http://cherrynews.com/best-nourishing-eye-serum . , The complimentary guide that is ... consumers who struggle with under eye puffiness. While surgical ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... Oklahoma (PRWEB) July 23, 2014 ... America’s leading provider of in-home care for seniors, ... Longevity Webinar Series featuring experts in a wide ... webinar will feature licensed clinical social worker and ... most common causes of caregiver stress and ways ...
(Date:7/23/2014)... 2014 In preparation for National Health ... Treatment Group is providing tips on choosing a reputable ... ever since man first figured out the process of ... existed since shortly thereafter. Its basis lies in the ... developing a way to combat that problem while monetizing ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, 2014 (HealthDay ... exposed to some form of childhood trauma than their civilian ... to apply solely to military men, not women. The ... for concern, given that early childhood exposure to various forms ... has been linked to a higher adult risk for depression, ...
Breaking Medicine News(10 mins):Health News:Puffy Eyes Serum Explored in Complimentary Guide Released at Consumer News Website 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 3Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 2Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 3
... cancer is the most common cancer diagnosed among men in ... There are several // treatment options, but new research shows ... , Doctors hope that the drug -- finasteride ... smaller doses, it’s commonly known as Propecia for baldness. It ...
... A new study finds angioplasty should be the treatment ... hospital they initially go to doesn’t offer angioplasty// services ... for treatment. ,Research has shown heart attack patients ... open up the clogged blood vessel that caused the ...
... New research reports, patients who were treated for depression ... vitamin B12 in their blood.// ,An increasing amount ... B and depression, but the specifics have not been ... relationship of vitamin B12 and the treatment of depression. ...
... A new study shows people who suffer from migraine headaches ... which are areas of the brain where the tissue has ... ages 30 to 60. They grouped the patients into categories ... no visual difficulties. A control group was also included in ...
... new study finds people who participated in a cardiac-rehab program ... rate // as those of the same age and sex ... about half of the deaths that occurred among patients in ... cardiac-rehab program. ,The investigation involved about 1,800 patients. Nearly ...
... from extremely low body fat whether due to strenuous ... from treatment with the appetite-and-weight-regulation hormone leptin.// The study ... instances of infertility. ,Leptin is produced in fat ... then travels to the brain and plays a role ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: